EMDR and Imagery Rescripting as a Treatment for Trauma-Related Intrusive Images

Conditions: PTSS
depression
PTSD
10027946

Registration Number: NL-OMON56857

Lead Sponsor: GGZ Eindhoven (Eindhoven)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 42

Inclusion Criteria

- Age between 18 and 70 years;
- Experiencing intrusions and/or nightmares;
- Meet criteria for unipolar depressive disorder, PTSD, or both disorders;
- Past aversive events still cause considerable distress;
- Be available for trauma treatment twice a week, with an additional coaching
session each week;
- Be proficient in the Dutch language.

Exclusion Criteria

- A dissociative identity disorder;
- Acute suicide risk;
- Acute psychosis;
- Substance use disorder;
- Bipolar disorder type 1 and 2.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome is a brief measure of characteristics of intrusions<br /><br>(specifically, the frequency, uncontrollability, and degree of interference<br /><br>with daily life), which will be assessed twice daily via an online link.<br /><br>Additionally, process measures indexing possible mediators concern brief<br /><br>questionnaires on emotion regulation, self-compassion, rumination, positive<br /><br>affect, and the vividness, distress, and related meaning of intrusions, which<br /><br>also serve as our primary outcome measures. These questionnaires will be<br /><br>assessed daily. All primary outcome measures will be administered during the<br /><br>baseline, experimental, and withdrawal phase.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcome measures concern questionnaires on quality of life,<br /><br>depression symptoms, and PTSD symptoms which are endorsed at baseline,<br /><br>post-treatment (i.e., 4 weeks after the last intervention session, at the end<br /><br>of the withdrawal phase), and at 6-month follow-up. A questionnaire about<br /><br>outcome expectancies will be administered at baseline, and weekly during the<br /><br>treatment phase.</p><br>